Nuvectis Pharma, Inc.(NVCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NVCT Nuvectis Pharma, Inc.

Trading 05-13 10:04:24 EDT

10.73

-0.17

-1.58%

High10.99	Low10.73	Vol1.86K
Open10.80	D1 Closing10.90	Amplitude2.41%
Mkt Cap284.55M	Tradable Cap165.98M	Total Shares26.53M
T/O20.15K	T/O Rate0.01%	Tradable Shares15.47M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NVCT","market":"US","secType":"STK","nameCN":"Nuvectis Pharma, Inc.","latestPrice":10.7275,"timestamp":1778681002247,"preClose":10.9,"halted":0,"volume":1860,"delay":0,"changeRate":-0.015825688073394607,"floatShares":15472700,"shares":26525533,"eps":-1.304517,"marketStatus":"Trading","change":-0.1725,"latestTime":"05-13 10:04:24 EDT","open":10.8,"high":10.99,"low":10.7275,"amount":20153.47944,"amplitude":0.024083,"askPrice":11,"askSize":230,"bidPrice":10.68,"bidSize":137,"shortable":3,"etf":0,"ttmEps":-1.304517,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1778702400000},"marketStatusCode":2,"adr":0,"listingDate":1638334800000,"exchange":"NASDAQ","adjPreClose":10.9,"preHourTrading":{"tag":"盘前","latestPrice":11.06,"preClose":10.9,"latestTime":"07:37 EDT","volume":88,"amount":973.2800000000001,"timestamp":1778672241016,"change":0.16,"changeRate":0.014679,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":10.9,"preClose":10.9,"latestTime":"17:52 EDT","volume":156,"amount":1700.82,"timestamp":1778622729194,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.160994,"impliedVol":1.1444,"impliedVolPercentile":0.6096},"requestUrl":"/m/hq/s/NVCT","defaultTab":"news","newsList":[{"id":"2633158317","title":"Analysts’ Top Healthcare Picks: Precision BioSciences (DTIL), Nuvectis Pharma (NVCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633158317","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633158317?lang=en_us&edition=fundamental","pubTime":"2026-05-07 00:50","pubTimestamp":1778086209,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Precision BioSciences (DTIL) and Nuvectis Pharma (NV...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-precision-biosciences-dtil-nuvectis-pharma-nvct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-precision-biosciences-dtil-nuvectis-pharma-nvct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","LABU","LU0029874061.USD","XBI","BK4588","NVCT","LU0128526141.USD","DTIL","HCSG","BK4581","BK4139","BK4585","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633910644","title":"Nuvectis Pharma Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633910644","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633910644?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:04","pubTimestamp":1777982666,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma Inc reports results for the quarter ended March 31 - Earnings SummaryNuvectis Pharma Inc NVCT.OQ reported a quarterly adjusted loss of 26 cents per share for the quarter ended March 31","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL8N41I1C5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633172149","title":"Nuvectis Pharma Q1 EPS $(0.26) Beats $(0.32) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633172149","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633172149?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:50","pubTimestamp":1777981837,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.32) by 18.75 percent. This is a 3.7 percent increase over losses of $(0.27) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52278150/nuvectis-pharma-q1-eps-0-26-beats-0-32-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633917518","title":"Nuvectis Q1 FY26 net loss widens to USD 6.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633917518","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633917518?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:33","pubTimestamp":1777980805,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma posted a net loss of USD 6.1 million, widening from USD 5.3 million.Research and development expenses rose to USD 4.1 million from USD 3.7 million, due to higher manufacturing costs, employee compensation and benefits, and clinical trial expenses.General and administrative costs climbed to USD 2.2 million from USD 1.9 million, on higher public company-related professional and consulting services.Cash and cash equivalents fell to USD 25.1 million at March 31, 2026 from USD 31.6 million at Dec. 31, 2025.NXP900 Phase 1b program continued enrolling patients in US monotherapy and combination arms; management expects a preliminary data readout in summer 2026, citing preclinical synergy with sotorasib in NSCLC models shown at AACR.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL8js6hv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00BN0W2T93.GBP","SG9999014013.SGD","BK4588","SG9999014021.USD","BK4585","IE00BKPKM429.USD","BK4112","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2W23.USD","LU2095319765.USD","IE00B3QW5Z07.USD","NDAQ","LU2210149790.SGD","IE00BN0W2V16.EUR","NVCT","SG9999014039.USD","SG9999014005.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633917867","title":"BRIEF-Nuvectis Pharma Q1 EPS USD -0.26","url":"https://stock-news.laohu8.com/highlight/detail?id=2633917867","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633917867?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:30","pubTimestamp":1777980645,"startTime":"0","endTime":"0","summary":"BRIEF-Nuvectis Pharma Q1 EPS USD -0.26\n\n\nMay 05 (Reuters) - Nuvectis Pharma Q1 operating income USD -6.26 million.\n\nQ1 net income USD -6.05 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nPLX0FF8BC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633917325","title":"Press Release: Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2633917325","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633917325?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:30","pubTimestamp":1777980600,"startTime":"0","endTime":"0","summary":"-- NXP900 Phase 1b clinical program continues to enroll patients at select. -- NXP900 preclinical presentations at the 2026 American Association for. Cancer Research  Annual Meeting\" further support the clinical. Mr. Bentsur concluded, \"We are excited for what's ahead in 2026 and expect a preliminary data readout from the NXP900 Phase 1b study in the summer. We continue to operate with financial discipline and remain focused on achieving key clinical development milestones in our NXP900 program in 2026 and beyond.\". General and administrative expenses were $2.2 million for the three months ended March 31, 2026, compared to $1.9 million for the three months ended March 31, 2025, an increase of $0.3 million. The increase was primarily driven by a $0.2 million increase in professional and consulting services related to public company expenses and a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632173886","title":"Nuvectis Pharma Inc  expected to post a loss of 31 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2632173886","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632173886?lang=en_us&edition=fundamental","pubTime":"2026-05-01 21:17","pubTimestamp":1777641426,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma Inc  expected to post a loss of31cents a share - Earnings Preview Nuvectis Pharma Inc NVCT.OQ NVCT.O is expected to  show no change in quarterly revenue when it reports  results on May","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nL8N41E108:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630310557","title":"Nuvectis Pharma announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2630310557","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630310557?lang=en_us&edition=fundamental","pubTime":"2026-04-28 04:38","pubTimestamp":1777322316,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma scheduled annual shareholder meeting to be held virtually on June 11, 2026.Shareholders set to vote on election of one Class I director for a three-year term.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvectis Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 27, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL9jCY2x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624559514","title":"Nuvectis to present Phase 1b NXP900 data at AACR meeting in April","url":"https://stock-news.laohu8.com/highlight/detail?id=2624559514","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624559514?lang=en_us&edition=fundamental","pubTime":"2026-04-01 06:30","pubTimestamp":1774996242,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma flagged upcoming 2026 AACR poster presentations for NXP900, a Phase 1b YES1/SRC inhibitor, scheduled for April 17-22 in San Diego.Data will be presented in the future, not previously disclosed in this announcement.Preclinical findings highlight stronger anti-tumor activity when NXP900 is combined with KRAS inhibitors in non-small cell lung cancer models.Additional studies describe a resistance mechanism in cholangiocarcinoma, with combination therapy positioned to restore drug sensitivity.Separate work suggests NXP900 could help re-engage anti-tumor immune responses in NSCLC by targeting immune-suppressive myeloid cells.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvectis Pharma Inc. published the original content u","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL9KY6n2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623458138","title":"BRIEF-Nuvectis Pharma Announces Upcoming Presentations For Nxp900 At The 2026 American Association","url":"https://stock-news.laohu8.com/highlight/detail?id=2623458138","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623458138?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:31","pubTimestamp":1774960296,"startTime":"0","endTime":"0","summary":"BRIEF-Nuvectis Pharma Announces Upcoming Presentations For Nxp900 At The 2026 American Association March 31 (Reuters) - Nuvectis Pharma Inc NVCT.O:NUVECTIS PHARMA ANNOUNCES UPCOMING PRESENTATIONS FOR ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUARKJBL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620275754","title":"Nuvectis Pharma management to meet with Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2620275754","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620275754?lang=en_us&edition=fundamental","pubTime":"2026-03-20 03:35","pubTimestamp":1773948917,"startTime":"0","endTime":"0","summary":"Meeting to be held on March 25 hosted by Maxim. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial new...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvectis-pharma-management-to-meet-with-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvectis-pharma-management-to-meet-with-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611934901","title":"Nuvectis Pharma Files $150 Million Mixed Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2611934901","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611934901?lang=en_us&edition=fundamental","pubTime":"2026-02-14 05:30","pubTimestamp":1771018246,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma  filed a shelf registration statement Friday with the US Securities and Exchange Commission for the potential sale of up to $150 million of securities from time to time.The filing covers the sale of the company's common stock, preferred stock, warrants, debt securities, and units comprising any combination of those securities.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611936361","title":"Nuvectis Pharma files $150M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2611936361","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611936361?lang=en_us&edition=fundamental","pubTime":"2026-02-14 05:05","pubTimestamp":1771016711,"startTime":"0","endTime":"0","summary":"16:03 EST Nuvectis Pharma (NVCT) files $150M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving br...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvectis-pharma-files-150m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvectis-pharma-files-150m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611198223","title":"Nuvectis Pharma Inc : Files for Mixed Shelf Offering of up to $150 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2611198223","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611198223?lang=en_us&edition=fundamental","pubTime":"2026-02-14 05:02","pubTimestamp":1771016527,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nFWN3Z91FS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610892955","title":"Nuvectis Pharma Q4 EPS $(0.31), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2610892955","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610892955?lang=en_us&edition=fundamental","pubTime":"2026-02-11 22:13","pubTimestamp":1770819199,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.31) per share which met the analyst consensus estimate. This is a 13.89 percent increase over losses of $(0.36) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50540929/nuvectis-pharma-q4-eps-0-31-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610932732","title":"Nuvectis Pharma Inc. FY25 net loss attributable to common shareholders widens to USD 28.87 million, up 52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610932732","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610932732?lang=en_us&edition=fundamental","pubTime":"2026-02-11 20:32","pubTimestamp":1770813167,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma Inc. reported its financial results for the full year ended December 31, 2025. Research and development expenses for the period totaled USD 18.15 million, while general and administrative expenses amounted to USD 9.42 million. The company recorded a finance income of USD 1.13 million. Operating loss for the year was USD 27.57 million, and net loss stood at USD 26.44 million. The total net loss attributable to common shareholders was USD 28.87 million, with basic and diluted net loss per common share at USD 1.32. Shareholders' equity as of December 31, 2025, was USD 18.41 million, and total liabilities and shareholders' equity reached USD 31.71 million. During the year, Nuvectis Pharma Inc. made significant progress in its NXP900 development program. The company highlighted advancements in the Phase 1b monotherapy study of NXP900, an oral small molecule inhibitor targeting the SRC Family of Kinases, including SRC and YES1. Management noted that these developments lay the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDLbn2Q5c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610932720","title":"Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2610932720","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610932720?lang=en_us&edition=fundamental","pubTime":"2026-02-11 20:30","pubTimestamp":1770813000,"startTime":"0","endTime":"0","summary":"FORT LEE, N.J., Feb.  11, 2026  (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (\"Nuvectis\" or the \"Company\"), a clinical-stage biopharmaceutical company focused on the development of innovat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/11/3236181/0/en/Nuvectis-Pharma-Inc-Reports-2025-Financial-Results-and-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592994042","title":"Nuvectis Pharma Announces the Initiation of the Phase 1B Study of Nxp900 in Combination With Osimertinib in Patients With Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2592994042","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592994042?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:00","pubTimestamp":1765972803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUADYJSQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592992590","title":"Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2592992590","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592992590?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:00","pubTimestamp":1765972800,"startTime":"0","endTime":"0","summary":"The study is designed to evaluate the safety and clinical activity of NXP900 in combination with osimertinib in patients with epidermal growth factor receptor mutated (EGFR mut+) non-small cell lung c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/17/3206848/0/en/Nuvectis-Pharma-Announces-the-Initiation-of-the-Phase-1b-Study-of-NXP900-in-Combination-with-Osimertinib-in-Patients-with-NSCLC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586912473","title":"Nuvectis Pharma Hosts Virtual Meeting on NXP900 Phase 1b Program in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2586912473","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586912473?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:00","pubTimestamp":1764075624,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma Inc. will host a virtual Key Opinion Leader Meeting on Tuesday, December 2, 2025, at 8:00 AM ET to discuss the NXP900 Phase 1b Program in advanced solid tumors, including its combination with osimertinib in non-small cell lung cancer. The event will feature experts including Dr. Alexander Spira and Dr. Asier Uncita-Broceta, and will cover key preclinical and clinical data and development strategies for NXP900. A live Q&A session will follow, and a replay will be available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvectis Pharma Inc. published the original content used to generate this news brief via GlobeNewswire  on November 25, 2025, and is solely responsible for the information contain","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDLbF7M1Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00B3QW5Z07.USD","BK4112","IE00B64PRP62.GBP","LU2210149790.SGD","LU2095319765.USD","LU2210150020.SGD","IE00BGHQF748.EUR","NVCT","BK4139","IE00BKPKM429.USD","BK4588","LU0314104364.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nuvectis.com","stockEarnings":[{"period":"1week","weight":0.1226},{"period":"1month","weight":0.326},{"period":"3month","weight":0.2415},{"period":"6month","weight":0.8412},{"period":"1year","weight":0.2999},{"period":"ytd","weight":0.4437}],"compareEarnings":[{"period":"1week","weight":0.0199},{"period":"1month","weight":0.0864},{"period":"3month","weight":0.0668},{"period":"6month","weight":0.0984},{"period":"1year","weight":0.2662},{"period":"ytd","weight":0.0825}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.130119},{"month":2,"riseRate":0.75,"avgChangeRate":0.147062},{"month":3,"riseRate":0.6,"avgChangeRate":0.077847},{"month":4,"riseRate":0.8,"avgChangeRate":0.055849},{"month":5,"riseRate":0.8,"avgChangeRate":0.219233},{"month":6,"riseRate":0,"avgChangeRate":-0.153353},{"month":7,"riseRate":0.25,"avgChangeRate":-0.099906},{"month":8,"riseRate":0.5,"avgChangeRate":-0.005612},{"month":9,"riseRate":0,"avgChangeRate":-0.100626},{"month":10,"riseRate":0.5,"avgChangeRate":-0.011793},{"month":11,"riseRate":0.25,"avgChangeRate":-0.090389},{"month":12,"riseRate":0.75,"avgChangeRate":0.071233}],"exchange":"NASDAQ","name":"Nuvectis Pharma, Inc.","nameEN":"Nuvectis Pharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nuvectis Pharma, Inc.(NVCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nuvectis Pharma, Inc.(NVCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nuvectis Pharma, Inc.,NVCT,Nuvectis Pharma, Inc.股票,Nuvectis Pharma, Inc.股票老虎,Nuvectis Pharma, Inc.股票老虎国际,Nuvectis Pharma, Inc.行情,Nuvectis Pharma, Inc.股票行情,Nuvectis Pharma, Inc.股价,Nuvectis Pharma, Inc.股市,Nuvectis Pharma, Inc.股票价格,Nuvectis Pharma, Inc.股票交易,Nuvectis Pharma, Inc.股票购买,Nuvectis Pharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nuvectis Pharma, Inc.(NVCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nuvectis Pharma, Inc.(NVCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}